CARDENE IV PREMIXED Rx
Generic Name and Formulations:
Nicardipine HCl 0.1mg/mL, 0.2mg/mL; soln for slow IV infusion.
Chiesi USA, Inc.
Indications for CARDENE IV PREMIXED:
Short-term treatment of hypertension when oral therapy is not feasible or desirable.
Individualize; see full labeling.
<18yrs: not recommended.
Advanced aortic stenosis.
Cardiac failure. Angina. Acute cerebral infarction or hemorrhage. Hepatic or renal impairment. Pheochromocytoma. For caps: measure blood pressure (BP) 1–2 hrs and 8 hrs after dosing. For IV: monitor BP before and during infusion; avoid rapid or excessive reductions; switch to oral form when possible. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by cimetidine. Increases serum levels of cyclosporine, tacrolimus; monitor and adjust its dose. Possibly potentiates digoxin; monitor.
Calcium channel blocker (CCB) (dihydropyridine).
Increased angina, flushing (caps), headache, pedal edema, asthenia, dizziness, somnolence (caps), tachycardia, GI upset, sweating; ECG abnormalities, orthostatic hypotension, ventricular extrasystoles, local reactions (inj).
Caps 20mg, 30mg—contact supplier; IV (10mL amps)—10; Premixed—200mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|